Search

Your search keyword '"Dalela, Disha"' showing total 25 results
Start Over Author "Dalela, Disha"
25 results on '"Dalela, Disha"'

1. Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers

Author

DiSilvestro, Jessica B., primary, Haddad, Jessica, additional, Robison, Katina, additional, Beffa, Lindsey, additional, Laprise, Jessica, additional, Scalia-Wilbur, Jennifer, additional, Raker, Christina, additional, Clark, Melissa A., additional, Lokich, Elizabeth, additional, Hofstatter, Erin, additional, Dalela, Disha, additional, Brown, Amy, additional, Bradford, Leslie, additional, Toland, Maris, additional, and Stuckey, Ashley, additional

Published
2024
Full Text
View/download PDF

4. POSTER: IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)

Author

Dalela, Disha, primary, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Muppidi, Jagan, additional, Steinberg, Seth, additional, Phelan, James, additional, Evans, Sarah, additional, Pradhan, Amynah, additional, Jaffe, Elaine, additional, Wilson, Wyndham, additional, Roschewski, Mark, additional, and Melani, Christopher, additional

Published
2023
Full Text
View/download PDF

5. IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)

Author

Dalela, Disha, primary, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Muppidi, Jagan, additional, Steinberg, Seth, additional, Phelan, James, additional, Evans, Sarah, additional, Pradhan, Amynah, additional, Jaffe, Elaine, additional, Wilson, Wyndham, additional, Roschewski, Mark, additional, and Melani, Christopher, additional

Published
2023
Full Text
View/download PDF

6. Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers

Author

DiSilvestro, Jessica B., primary, Haddad, Jessica, additional, Robison, Katina, additional, Beffa, Lindsey, additional, Laprise, Jessica, additional, Scalia-Wilbur, Jennifer, additional, Raker, Christina, additional, Clark, Melissa, additional, Lokich, Elizabeth, additional, Hofstatter, Erin, additional, Dalela, Disha, additional, Brown, Amy, additional, Bradford, Leslie, additional, Toland, Maris, additional, and Stuckey, Ashley, additional

Published
2023
Full Text
View/download PDF

8. Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383)

Author

DiSilvestro, Jessica, primary, Dexter, Julia, additional, Haddad, Jessica, additional, Beffa, Lindsey, additional, Raker, Christina, additional, Laprise, Jessica, additional, Wilbur, Jennifer Scalia, additional, Clark, Melissa, additional, Bradford, Leslie, additional, Brown, Amy, additional, Hofstatter, Erin, additional, Dalela, Disha, additional, Toland, Maris, additional, Robison, Katina, additional, and Stuckey, Ashley, additional

Published
2022
Full Text
View/download PDF

10. Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2mutation carriers

Author

DiSilvestro, Jessica B., Haddad, Jessica, Robison, Katina, Beffa, Lindsey, Laprise, Jessica, Scalia-Wilbur, Jennifer, Raker, Christina, Clark, Melissa, Lokich, Elizabeth, Hofstatter, Erin, Dalela, Disha, Brown, Amy, Bradford, Leslie, Toland, Maris, and Stuckey, Ashley

Abstract

BRCAmutation carriers frequently undergo prophylactic bilateral salpingo-oophorectomy at young ages and less than half report using hormone therapy due to barriers including patient fears and physician discouragement.

Published
2023
Full Text
View/download PDF

12. Additional file 1 of Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes

Author

Rozenblit, Mariya, Hofstatter, Erin, Liu, Zuyun, O���Meara, Tess, Storniolo, Anna Maria, Dalela, Disha, Singh, Vineet, Pusztai, Lajos, and Levine, Morgan

Subjects
skin and connective tissue diseases
Abstract

Additional file 1. Fig. S1. Consort diagram of breast tissue and peripheral blood samples. Fig. S2. Correlations between age and six epigenetic clocks in controls (top row) and cases (bottom row) in breast tissue. Fig. S3. Epigenetic clock accelerations in cases (normal breast tissue > 3 cm away from breast tumor in breast cancer patients) and controls (normal breast tissue from healthy individuals) adjusted for confounders (race, smoking, BMI). Fig. S4. Correlations between age and epigenetic clocks in controls (top row) and cases (bottom row) in peripheral blood. Fig. S5. Using the CpGs in the Levine clock that are associated with polycomb-related genes, we estimated Mahalanobis distance using DNA methylation levels from breast tumor samples as a reference. We then tested whether samples became more tumor like (lower distance) with age in cases (A) and controls (B). When comparing cases to controls, we found that cases had a DNA methylation profile with a lower Mahalanobis distance suggesting they were more breast tumor like (C).

Published
2022
Full Text
View/download PDF

16. Family planning in carriers ofBRCA1andBRCA2pathogenic variants

Author

Haddad, Jessica M., primary, Robison, Katina, additional, Beffa, Lindsey, additional, Laprise, Jessica, additional, ScaliaWilbur, Jennifer, additional, Raker, Christina A., additional, Clark, Melissa A., additional, Hofstatter, Erin, additional, Dalela, Disha, additional, Brown, Amy, additional, Bradford, Leslie, additional, Toland, Maris, additional, and Stuckey, Ashley, additional

Published
2021
Full Text
View/download PDF

19. Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.

Author

Patel, Shyam A., Dalela, Disha, Fan, Amy C., Lloyd, Maxwell R., and Zhang, Tian Y.

Subjects
*ACUTE myeloid leukemia, *STEM cell niches, *HEMATOPOIETIC stem cells, *BONE marrow, *CYTOLOGY
Abstract

Acute myeloid leukemia (AML) is an aggressive malignancy of stem cell origin that contributes to significant morbidity and mortality. The long-term prognosis remains dismal given the high likelihood for primary refractory or relapsed disease. An essential component of relapse is resurgence from the bone marrow. To date, the murine hematopoietic stem cell (HSC) niche has been clearly defined, but the human HSC niche is less well understood. The design of niche-based targeted therapies for AML must account for which cellular subsets compete for stem cell occupancy within respective bone marrow microenvironments. In this review, we highlight the principles of stem cell niche biology and discuss translational insights into the AML microenvironment as of 2021. Optimization of competition for niche occupancy is important for the elimination of measurable residual disease (MRD). Some of these novel therapeutics are in the pharmacologic pipeline for AML and may be especially useful in the setting of MRD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

20. Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.

Author

Haddad, Jessica M., Robison, Katina, Beffa, Lindsey, Laprise, Jessica, ScaliaWilbur, Jennifer, Raker, Christina A., Clark, Melissa A., Hofstatter, Erin, Dalela, Disha, Brown, Amy, Bradford, Leslie, Toland, Maris, and Stuckey, Ashley

Abstract

BRCA1 and BRCA2 pathogenic variant carriers have a high lifetime risk of developing breast and ovarian malignancies. Given the risks and significant ramifications of undergoing risk‐reducing surgeries, many pathogenic variant carriers unaffected by cancer (previvors) struggle with family planning and reproductive decision making. The objective of this study was to determine the attitudes and practices of BRCA1 and BRCA2 pathogenic variant carriers with respect to family planning decision making. A cross‐sectional survey was conducted of BRCA1 and BRCA2 previvors at four Northeastern medical centers. The survey was administered electronically via email using REDCap. The survey included demographic information as well as questions about genetic testing, prophylactic surgeries, family planning, and partnering. Data were analyzed with Fisher's exact tests and t tests. The survey was completed by 139 of 422 BRCA1 and BRCA2 pathogenic variant carriers (response rate 33%). Thirteen were excluded from analysis due to self‐reported cancer history. Of the remaining 126, 21 (16.7%) were male and 105 (83.3%) were female. Female participants <35 years old at the time of genetic testing were significantly more likely than those 35 or greater to report feeling urgency to have a family after finding out about their BRCA1 and BRCA2 pathogenic variant (p < 0.0001). Younger women also reported their genetic status had a stronger impact on their romantic relationships (p = 0.029). Men were significantly more likely to report that they felt no urgency to have a family compared to women (p < 0.0001). Our study reflects the complex decision making for previvors and the intricacies of family planning in this population. Providers can use this knowledge as a guide to counsel patients about reproductive options. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Nivolumab in Lymphomatoid Granulomatosis (LYG) and Other Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPDs) and Non-Hodgkin Lymphomas (NHLs) with Systemic and/or CNS Involvement: Preliminary Analysis of Efficacy and Safety from an Ongoing Phase II Study

Author

Dalela, Disha, Lakhotia, Rahul, Pittaluga, Stefania, Muppidi, Jagan R., Phelan, James D, Pradhan, Amynah, Evans, Sarah, Morrison, Candis, Tadese, Atekelt, Steinberg, Seth M., Cohen, Jeffrey, Jaffe, Elaine S., Wilson, Wyndham H, Roschewski, Mark, and Melani, Christopher

Abstract

Background:Programmed cell death protein-1 (PD-1) is a signaling molecule on the surface of T-cells that suppresses the cytotoxic effects of T-cells on tumor cells. We previously demonstrated increased PD-1 expression on CD8+ T-cells compared to healthy controls in pts with LYG, which could be reversed with immunotherapy using interferon alpha-2b (Melani et al. Lancet Haematol. 2023). Additionally, elevated expression of programmed death-ligand 1 (PD-L1) has been observed in other EBV-LPDs and NHLs as well as in chronic viral infections, such as EBV. Given this likely shared disease pathobiology, we hypothesized that treatment with the anti-PD-1 antibody, nivolumab, may reverse T-cell exhaustion and result in anti-tumor responses in pts with LYG and other EBV-LPDs and NHLs, including those with systemic and/or CNS involvement.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results